PPARD and metabolic syndrome: Thus, while both agonists alleviate the effects of T2DM by potentially decreasing the lipid load on peripheral tissue and the induction of insulin resistance by lipotoxicity [31], stimulation of PPARδ may also reduce obesity, thus being a potent target for the treatment of the metabolic syndrome.